Post-infectious aplasia from Parvovirus B19 is an acquired condition characterized by selective and transient suppression of the erythroid bone marrow lineage, secondary to Parvovirus B19 infection. It primarily affects patients with pre-existing chronic hemolytic diseases or immunocompromised individuals but may also occur in immunocompetent subjects. The disease presents with severe anemia and marked reticulocytopenia, often without alterations of other blood cell lines.
Etiology, Pathogenesis, and Pathophysiology
The direct cause of aplasia is infection by Parvovirus B19, a small single-stranded DNA virus belonging to the Parvoviridae family. This virus exhibits a strong tropism for erythroid progenitor cells, particularly erythroblasts, through interaction with the P antigen receptor expressed on their surface.
The virus enters erythroid cells through receptor-mediated endocytosis, leading to:
Cell cycle arrest in S phase, preventing cellular DNA replication.
Caspase activation and induction of apoptosis in erythroid precursors.
Reduced erythropoietin secretion secondary to fever and systemic inflammatory stress.
The result is an interruption of erythrocyte production, which in healthy individuals may go unnoticed or cause only mild transient anemia. In patients with chronic hemolytic disorders (such as hereditary spherocytosis, sickle cell disease, beta-thalassemia) or immunodeficiency, the accelerated destruction of red blood cells combined with impaired production rapidly leads to clinically significant bone marrow aplasia.
In immunocompromised individuals (e.g., HIV, transplant recipients, leukemia patients), ineffective viral clearance can lead to persistent chronic infection with prolonged erythroid aplasia or even global pancytopenia.
Risk Factors and Prevention
Main risk factors for developing clinically relevant aplasia after Parvovirus B19 infection include:
Immunodeficiency (primary immunodeficiencies, HIV, immunosuppressive therapy, organ transplantation).
Pregnancy (risk of non-immune hydrops fetalis in case of primary maternal infection).
Currently, there are no approved vaccines against Parvovirus B19 in humans. Prevention is based on:
Hygienic measures (handwashing, surface disinfection) during community outbreaks.
Exposure control in hematology, pediatrics, and neonatology units.
Passive prophylaxis with immunoglobulins in exposed immunocompromised individuals (in selected cases).
Clinical Manifestations
The clinical presentation of post-infectious aplasia varies depending on immune status and the presence of underlying hemolytic diseases.
In immunocompetent individuals, the disease usually presents with:
Rapid-onset severe anemia associated with marked pallor, profound asthenia, and exertional dyspnea.
Mild or absent fever at presentation, although there may be a recent history of mild viral infection (such as "fifth disease" rash in children).
In immunocompromised patients or those with chronic hemolysis:
Severe aplastic crises requiring urgent blood transfusions.
Chronic hypoplastic crises with progressive erythroid depletion, sometimes accompanied by neutropenia or thrombocytopenia in cases of persistent infection.
Complex hematologic pictures mimicking myelodysplastic syndromes or acute leukemia.
Diagnosis
The diagnostic suspicion arises in cases of acute-onset severe anemia with marked reticulocytopenia (<1%), especially in patients with hemolytic diseases or immunosuppression.
Main diagnostic investigations include:
Complete blood count and peripheral smear: normocytic or slightly macrocytic anemia, reduced reticulocytes, normal white cell and platelet counts.
Bone marrow examination (in selected cases): selective erythroid hypoplasia with preserved granulopoiesis and megakaryopoiesis; presence of giant erythroblasts with viral nuclear inclusions.
Viral DNA detection through quantitative PCR on peripheral blood or bone marrow, highly sensitive and specific.
Anti-Parvovirus B19 IgM antibody testing, indicative of recent infection (useful in immunocompetent patients).
Differential diagnosis includes:
Aplastic anemia (global pancytopenia and hypocellular marrow).
Diamond-Blackfan anemia (present from infancy with associated congenital anomalies).
